Sun Pharma updates on Ranbaxy Generic Drug Application Antitrust Litigation in US

On November 27, 2019, the US District Court (District of Massachusetts) entered a decision denying in part and granting in part Sun Pharma Ltd’s motion to dismiss the claims of certain plaintiffs.

New Delhi: Drugmaker, Sun Pharmaceuticals Ltd. recently informed that the company along with its wholly-owned subsidiaries (together “Sun Pharma”) is a defendant in a multi-district litigation brought by various classes of plaintiffs, in the US District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs (Valganciclovir, Valsartan and Esomeprazole).

The complaints assert claims under the Racketeer Influenced and Corrupt Organizations Act, federal and state antitrust laws, and state consumer protection laws.

These litigations have already been disclosed in the Company’s 2018-19 annual report, Sun Pharma said in a filing.

Updating the BSE on the case, Sun Pharma said that On November 27, 2019, the US District Court (District of Massachusetts) entered a decision denying in part and granting in part Sun Pharma’s motion to dismiss the claims of certain plaintiffs. Under the ruling, the majority of those plaintiff’s claims survive and several state law claims are dismissed. The litigation is proceeding in discovery.

"Sun Pharma will continue to vigorously defend against all claims and is also considering its appeal options as to the claims that were not dismissed in the above court decision," the company added.